(Q46882549)

English

Pegase 03: a prospective randomized phase III trial of FEC with or without high-dose thiotepa, cyclophosphamide and autologous stem cell transplantation in first-line treatment of metastatic breast cancer

scientific article published on 26 November 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/18037940

Pegase 03: a prospective randomized phase III trial of FEC with or without high-dose thiotepa, cyclophosphamide and autologous stem cell transplantation in first-line treatment of metastatic breast cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/18037940

phase III clinical trial

0 references

author name string

Biron P

1

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/18037940

Durand M

2

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/18037940

Roché H

3

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/18037940

Delozier T

4

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/18037940

Battista C

5

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/18037940

Fargeot P

6

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/18037940

Spaeth D

7

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/18037940

Bachelot T

8

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/18037940

Poiget E

9

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/18037940

Monnot F

10

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/18037940

Tanguy ML

11

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/18037940

Curé H

12

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/18037940

language of work or name

0 references

publication date

26 November 2007

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/18037940

Bone Marrow Transplantation

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/18037940

41

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/18037940

6

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/18037940

555-562

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/18037940

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1705935

0 references

Breast cancer with synchronous metastases: trends in survival during a 14-year period

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705935

21 January 2018

Molecular portraits of human breast tumours

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705935

21 January 2018

High-dose chemotherapy and stem cell support for breast cancer: where are we now?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705935

21 January 2018

Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705935

21 January 2018

Taxane/anthracycline combinations: setting a new standard in breast cancer?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705935

21 January 2018

A critique of the eleven randomised trials of high-dose chemotherapy for breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705935

21 January 2018

Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705935

21 January 2018

High-dose chemotherapy with reinfusion of purged autologous bone marrow following dose-intense induction as initial therapy for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705935

21 January 2018

Tables of the number of patients required in clinical trials using the logrank test.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705935

21 January 2018

Toxicity of the high-dose chemotherapy CTC regimen (cyclophosphamide, thiotepa, carboplatin): the Netherlands Cancer Institute experience

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705935

21 January 2018

A randomized phase III comparative trial of immediate consolidation with high-dose chemotherapy and autologous peripheral blood progenitor cell support compared to observation with delayed consolidation in women with metastatic breast cancer and onl

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705935

21 January 2018

Consolidation with high-dose combination alkylating agents with bone marrow transplantation significantly improves disease-free survival in hormone-insensitive metastatic breast cancer in complete remission compared with intensive standard-dose chem

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705935

21 January 2018

Should we continue to study high-dose chemotherapy in metastatic breast cancer patients? A critical review of the published data

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705935

21 January 2018

High-dose chemotherapy in breast cancer: where are we now?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705935

21 January 2018

Autologous hematopoietic stem cell transplantation for breast cancer in Europe: critical evaluation of data from the European Group for Blood and Marrow Transplantation (EBMT) Registry 1990-1999.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705935

21 January 2018

Phase II trial of sequential high-dose chemotherapy with paclitaxel, melphalan and cyclophosphamide, thiotepa and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705935

21 January 2018

A phase I/II study of 4 monthly courses of high-dose cyclophosphamide and thiotepa for metastatic breast cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705935

21 January 2018

Targeted therapy: wave of the future.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705935

21 January 2018

Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705935

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705935

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705935

7 January 2021

based on heuristic

inferred from DOI database lookup

The importance of dose intensity in chemotherapy of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705935

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705935

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705935

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705935

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose consolidation therapy with autologous stem-cell rescue in stage IV breast cancer: follow-up report

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705935

7 January 2021

based on heuristic

inferred from DOI database lookup

The controversy over high-dose chemotherapy with autologous bone marrow transplant for breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705935

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose chemotherapy for breast cancer: the French PEGASE experience

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705935

7 January 2021

based on heuristic

inferred from DOI database lookup

[Intensive chemotherapy and autograft of hematopoietic stem cells in the treatment of metastatic cancer: results of the national protocol Pegase 04]

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705935

7 January 2021

based on heuristic

inferred from DOI database lookup

Tumor cell contamination of bone marrow harvest products: clinical consequences in a cohort of advanced-stage breast cancer patients undergoing high-dose chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705935

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705935

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.BMT.1705935

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/18037940

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/18037940

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46882549&oldid=2135666551"